CO-ADD is a global initiative of The University of Queensland’s Institute for Molecular Bioscience (UQ IMB) and is funded by Wellcome Trust and UQ. We perform primary antimicrobial screening free of charge for academic research groups.
We have spent the last 3 years standardising assays and workflows to be able to screen for, and then validate, new anti-microbials in 384 well format. We are seeking to access novel chemical diversity from academic synthetic chemists that lies outside that already screened by Pharma.
In the primary screening we test against key ESKAPE pathogens, E. coli, K. pneumoniae, A. baumannii, P. aeruginosa, S. aureus (MRSA), as well as the fungi C. neoformans and C. albicans. If we get any hits here we have more specific panels that include MDR, Pan-resistant bacterial strains and clinical isolates that we can re-screen the compounds against. Additionally with hits we back screen for cytotoxicity, compound aggregation and human red blood cell haemolysis.
We only need 1 mg of dry compound or 50uL at 10 mg/mL in DMSO, and you do not need to provide a structure.
Should you have larger or smaller amounts of compounds or a compound library already prepared in a different format please contact CO-ADD for alternative format options of compound supply.
We require all compounds to be soluble in DMSO and to be shipped as dry material in appropriate containers, such as 1-2 mL Eppendorf tubes. For larger collections we can arrange plates or tube-racks.
As required under Australian Quarantine regulations, if you are located outside of Australia CO-ADD will arrange for sample importation documents, and if required will support sample shipping costs.
This is a free service and we make no claims on results or IP. You will have 18 months to publish or patent your positive hits. The data will then be made available in an open access database for use by the community.
Send your compounds today! www.co-add.org